MA34464B1 - Procede pour la preparation de formes enantiomeres de derives d'acide 2,3- diaminopropionique - Google Patents

Procede pour la preparation de formes enantiomeres de derives d'acide 2,3- diaminopropionique

Info

Publication number
MA34464B1
MA34464B1 MA35657A MA35657A MA34464B1 MA 34464 B1 MA34464 B1 MA 34464B1 MA 35657 A MA35657 A MA 35657A MA 35657 A MA35657 A MA 35657A MA 34464 B1 MA34464 B1 MA 34464B1
Authority
MA
Morocco
Prior art keywords
preparation
acid derivatives
diaminopropionic acid
separation
enantiomer forms
Prior art date
Application number
MA35657A
Other languages
English (en)
Inventor
Claus-Dieter Graf
Joerg Rieke-Zapp
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34464(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA34464B1 publication Critical patent/MA34464B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un procédé pour la préparation des formes énantiomères de dérivés d'acide 2,3-diaminopropionique de formule (I), où R1, R2 et R3 sont définis comme décrit dans les revendications, par séparation d'un racémique. La séparation du racémique en ses énantiomères est effectuée par formation de sels diastéréoisomères après ajout d'un adjuvant énantiomère pur, et ensuite séparation par cristallisation fractionnée.
MA35657A 2010-08-12 2011-08-05 Procede pour la preparation de formes enantiomeres de derives d'acide 2,3- diaminopropionique MA34464B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305884 2010-08-12
US201061428336P 2010-12-30 2010-12-30
PCT/EP2011/063504 WO2012019967A1 (fr) 2010-08-12 2011-08-05 Procédé pour la préparation de formes énantiomères de dérivés d'acide 2,3-diaminopropionique

Publications (1)

Publication Number Publication Date
MA34464B1 true MA34464B1 (fr) 2013-08-01

Family

ID=43598042

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35657A MA34464B1 (fr) 2010-08-12 2011-08-05 Procede pour la preparation de formes enantiomeres de derives d'acide 2,3- diaminopropionique

Country Status (24)

Country Link
US (2) US8877926B2 (fr)
EP (1) EP2603491B1 (fr)
JP (1) JP6000248B2 (fr)
KR (1) KR20130099044A (fr)
CN (1) CN103209961A (fr)
AR (1) AR082621A1 (fr)
AU (1) AU2011288533A1 (fr)
BR (1) BR112013002985A2 (fr)
CA (1) CA2807979A1 (fr)
CL (1) CL2013000420A1 (fr)
CO (1) CO6690757A2 (fr)
CR (1) CR20130059A (fr)
DO (1) DOP2013000035A (fr)
EC (1) ECSP13012434A (fr)
GT (1) GT201300038A (fr)
MA (1) MA34464B1 (fr)
MX (1) MX2013001647A (fr)
PE (1) PE20131326A1 (fr)
PH (1) PH12013500256A1 (fr)
RU (1) RU2013110525A (fr)
SG (1) SG187791A1 (fr)
TW (1) TW201221504A (fr)
UY (1) UY33552A (fr)
WO (1) WO2012019967A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2856607C (fr) 2011-12-06 2020-03-10 Sanofi Formes cristallines du [(s)-1-carbamoyl-2-(phenylpyrimidin-2-ylamino)ethyl]amide de l'acide 2-(2-methylaminopyrimidin-4-yl)-1h-indole-5-carboxylique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19850301A1 (de) * 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
US7462638B2 (en) 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
US20070142417A1 (en) 2005-05-11 2007-06-21 Aventis Pharmaceuticals Inc Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
DE102005025225A1 (de) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten

Also Published As

Publication number Publication date
CL2013000420A1 (es) 2013-04-05
US8877926B2 (en) 2014-11-04
CN103209961A (zh) 2013-07-17
JP6000248B2 (ja) 2016-09-28
DOP2013000035A (es) 2013-03-15
EP2603491B1 (fr) 2014-09-24
WO2012019967A1 (fr) 2012-02-16
ECSP13012434A (es) 2013-03-28
SG187791A1 (en) 2013-03-28
CO6690757A2 (es) 2013-06-17
PE20131326A1 (es) 2013-11-12
RU2013110525A (ru) 2014-09-20
CA2807979A1 (fr) 2012-02-16
BR112013002985A2 (pt) 2017-11-07
US20150018554A1 (en) 2015-01-15
TW201221504A (en) 2012-06-01
AR082621A1 (es) 2012-12-19
MX2013001647A (es) 2013-03-21
GT201300038A (es) 2015-06-24
UY33552A (es) 2012-03-30
JP2013533296A (ja) 2013-08-22
PH12013500256A1 (en) 2013-03-18
US9434696B2 (en) 2016-09-06
KR20130099044A (ko) 2013-09-05
US20130211085A1 (en) 2013-08-15
AU2011288533A1 (en) 2013-02-28
CR20130059A (es) 2013-03-25
EP2603491A1 (fr) 2013-06-19

Similar Documents

Publication Publication Date Title
JP5683761B1 (ja) 光学活性な二環性γ−アミノ酸誘導体の製造方法
GEP20125621B (en) 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor
AU2011222644A1 (en) Improved resolution methods for isolating desired enantiomers of tapentadol intermediates and use thereof for the preparation of tapentadol
KR101624760B1 (ko) 광학적 활성 （ｓ）-（-）-（2）-（ｎ-프로필아미노）-５-메톡시테트라린 화합물 및 광학적 활성（ｓ）-（-）-２-（ｎ-프로필아미노）-５-하이드록시테트라민 화합물의 제조방법
US8877941B2 (en) Process for the resolution of medetomidine and recovery of the unwanted enantiomer
EA201291116A1 (ru) Способ получения метансульфонатных солей ралфинамида или их r-энантиомеров
KR20120133774A (ko) 키랄 팔라듐 촉매를 이용한 베타-인돌릴 에스테르 화합물의 제조방법
MA34464B1 (fr) Procede pour la preparation de formes enantiomeres de derives d'acide 2,3- diaminopropionique
JP2009509958A (ja) ナフチルアルキルアミンによるα−（フェノキシ）フェニル酢酸誘導体の分割
JP2013245215A (ja) 不斉環化反応による光学活性二環性化合物の製造方法
KR101304640B1 (ko) 신규의 로수바스타틴 엔-메틸벤질아민 염 및 그의 제조방법
EA036157B1 (ru) Способ синтеза промежуточных соединений небиволола
JP2007513936A (ja) ネフォパムの分割のための方法
WO2016142165A1 (fr) Procédé amélioré de purification optique d'ésoméprazole
FR3054218B1 (fr) Procede de dedoublement de sels de baclofene
DE602006008335D1 (de) Neuartiges verfahren zur herstellung von quaternärer säure und ammoniumsalzen
JP4126921B2 (ja) 光学活性なβ−フェニルアラニン誘導体の製造方法
WO2012070896A3 (fr) Procédé de synthèse d'un acide 2,2'-dihydroxy-1,1'-binaphtyl-3-carboxylique énantiomériquement pur
JP6234999B2 (ja) 光学的に活性な３，３−ジフェニルプロピルアミンを調製するための方法
JP2016222628A (ja) デュロキセチン塩酸塩の製造方法
JP3828197B2 (ja) 光学活性３−（ｐ−メトキシフェニル）グリシッド酸アルカリ金属塩の製造法
WO2013089189A1 (fr) Procédé de résolution optique pour composé bicyclique utilisant de l'acide hydroxysulfonique
MX2014003509A (es) Procesos e intermediarios para la preparacion de un inhibidor macrociclico de la protesta del virus de la hepatitis c.
ES2309416T3 (es) Procedimiento estereoselectivo para la preparacion de clopidogrel.
MX2019015095A (es) Metodo de sintesis para producir compuestos de cis-imidazolina enantiomericamente puros para uso farmaceutico.